USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 11, 2022 | Jun 2022 | $-1.08 | - | $-0.92 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 11, 2022 | Jun 2022 | $0.00 | - | $0.00 |
Forma Therapeutics's next earnings date is Thursday, Aug 11, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Jun 2022 | 5 | $-1.08 | $-1.18 | $-0.99 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 6 | $-4.28 | $-4.86 | $-3.79 |
| Dec 2023 | 5 | $-3.90 | $-4.86 | $-3.31 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Jun 2022 | 0 / 0 | $-0.99 | $-0.97 | $-0.97 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 1 / 0 | $-3.88 | $-3.65 | $-3.65 |
| Dec 2023 | 1 / 0 | $-3.83 | $-3.65 | $-3.65 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Jun 2022 | 4 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 5 | $1.06M | $0.00 | $5.00M |
| Dec 2023 | 5 | $3.96M | $0.00 | $10.40M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| May 6, 2022 | Mar 2022 | $-1.05 | - | - |
| Mar 1, 2022 | Dec 2021 | $-0.96 | $-1.06 | -10.42% |
| Nov 12, 2021 | Sep 2021 | $-0.96 | $-0.91 | 5.35% |
| Aug 13, 2021 | Jun 2021 | $-0.79 | $-0.92 | -16.03% |
| May 14, 2021 | Mar 2021 | $-0.76 | $-0.76 | -0.66% |
| Mar 30, 2021 | Dec 2020 | $-0.80 | $-0.68 | 15.00% |
| Nov 12, 2020 | Sep 2020 | $-0.68 | $-0.67 | 1.11% |
| Aug 13, 2020 | Jun 2020 | $-0.95 | $-0.66 | 30.48% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 1, 2022 | Dec 2021 | $-3.56 | $-3.65 | - |
| Mar 30, 2021 | Dec 2020 | $-3.64 | $-2.01 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| May 6, 2022 | Mar 2022 | $0.00 | - | - |
| Mar 1, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Nov 12, 2021 | Sep 2021 | $0.00 | $0.00 | - |
| Aug 13, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 14, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 30, 2021 | Dec 2020 | $200.00K | $0.00 | - |
| Nov 12, 2020 | Sep 2020 | $500.00K | $0.00 | - |
| Aug 13, 2020 | Jun 2020 | $500.00K | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 1, 2022 | Dec 2021 | $0.00 | $0.00 | - |
| Mar 30, 2021 | Dec 2020 | $170.00K | $0.00 | - |
FMTX's next earnings date is Thursday, Aug 11, 2022 for the fiscal quarter ending Jun 30, 2022.
According to analysts, the average EPS estimation for Forma Therapeutics's next quarterly earnings is $-1.08, with a low EPS estimation of $-1.18, and a high estimation of $-0.99.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.99, the last 2 month trend is $-0.97, and the 3 month trend is $-0.97.
Based on analysts, the average revenue estimation is $0.00, with a low revenue estimation of $0.00, and a high estimation of $0.00.
Forma Therapeutics's previous earnings date was May 6, 2022 for its fiscal quarter ended Mar 31, 2022.
The company reported a net income of $-44.16M.Free cash flow for the quarter was $-49.56M , compared to $-41.66M last quarter and $-41.32M a year before.
FMTX ended the quarter with $32.08M in total debt, a decrease of -2.02% compared to the previous quarter, and an increase of 288.60% compared to the same quarter a year before.
Forma Therapeutics's previous annual earnings date was Mar 1, 2022 for its fiscal year ended Dec 31, 2021.
FMTX's earnings per share (EPS) was $-3.65, missing the consensus analysts forecast of $-3.56 by 2.53% , and lower than the previous year's EPS (Dec 2020) by 81.37%.
Revenues were $0.00.
The company reported a net income of $-172.96M.
Forma Therapeutics reported a free cash flow of $-153.97M for its fiscal year, compared to $-95.67M a year ago.
The company ended the fiscal year with $32.74M in total debt. lala
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
